Baroda BNP Paribas Health & Wellness Growth Direct Plan
SIP amount
Min. ₹500
Lumpsum amount
Min. ₹1,000

Baroda BNP Paribas Health & Wellness Growth Direct Plan

NAV
₹9.6051
+0.06%
(24 Feb)
AUM
545 Cr
TER
0.6%
Risk
Very High Risk
Insights
Total Expense Ratio (TER) is in the bottom 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+33.4%
+31.7%
+31.1%
+25.8%
NA
3Y
+37.1%
+34.0%
+34.4%
+32.6%
NA
5Y
+29.5%
+29.1%
+27.8%
NA
NA
ALL
+12.8%
+25.9%
+17.1%
+28.8%
-4.0%
VOL
20.0%
21.8%
19.6%
17.1%
9.9%
TER
0.8%
0.6%
0.9%
0.9%
0.6%
AUM
₹5,980 Cr
₹5,714 Cr
₹1,492 Cr
₹1,924 Cr
₹545 Cr
INFO
0.64
1.19
0.87
1.68
-0.40
See fund holdings as of 31st Jan
Top holdings
Sun Pharmaceuticals Industries Ltd
8.5%
Mankind Pharma Ltd
7.4%
Cipla Ltd
6.3%
Max Healthcare Institute Ltd Ordinary Shares
5.8%
Abbott India Ltd
5.0%
Lupin Ltd
4.9%
Torrent Pharmaceuticals Ltd
4.7%
Aster DM Healthcare Ltd Ordinary Shares
4.6%
AstraZeneca Pharma India Ltd
4.1%
Ipca Laboratories Ltd
3.9%
Top industry exposure
Healthcare
92.9%
Financial Services
3.9%
Other information
Minimum SIP
₹500
Minimum lumpsum
₹1,000
Additional lumpsum
₹1,000
Portfolio turnover
39%
Lock-in period
-
Exit load
• 1% for redemption within 365 days
Fund objective
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
Fund manager(s)
Sanjay Chawla

FAQs